WallStSmart

Crowdstrike Holdings Inc (CRWD)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 1216% more annual revenue ($63.32B vs $4.81B). PFE leads profitability with a 11.8% profit margin vs -3.4%. CRWD appears more attractively valued with a PEG of 3.93. PFE earns a higher WallStSmart Score of 55/100 (C).

CRWD

Hold

40

out of 100

Grade: D

Growth: 9.3Profit: 2.5Value: 3.0Quality: 5.5
Piotroski: 2/9Altman Z: 0.98

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CRWDSignificantly Overvalued (-27.0%)

Margin of Safety

-27.0%

Fair Value

$398.25

Current Price

$527.77

$129.52 premium

UndervaluedFair: $398.25Overvalued
PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRWD4 strengths · Avg: 9.0/10
EPS GrowthGrowth
533.0%10/10

Earnings expanding 533.0% YoY

Market CapQuality
$128.72B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
23.3%8/10

Revenue surging 23.3% year-over-year

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

CRWD4 concerns · Avg: 2.5/10
Operating MarginProfitability
1.0%3/10

Operating margin of 1.0%

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
3.932/10

Expensive relative to growth rate

Price/BookValuation
30.2x2/10

Trading at 30.2x book value

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : CRWD

The strongest argument for CRWD centers on EPS Growth, Market Cap, Debt/Equity. Revenue growth of 23.3% demonstrates continued momentum.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : CRWD

The primary concerns for CRWD are Operating Margin, Piotroski F-Score, PEG Ratio.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

CRWD profiles as a growth stock while PFE is a value play — different risk/reward profiles.

CRWD carries more volatility with a beta of 1.06 — expect wider price swings.

CRWD is growing revenue faster at 23.3% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Bottom Line

PFE scores higher overall (55/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Crowdstrike Holdings Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

CrowdStrike Holdings, Inc. provides cloud solutions for endpoint and cloud workload protection in the United States, Australia, Germany, India, Israel, Romania, and the United Kingdom. The company is headquartered in Sunnyvale, California.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?